ADVFN - Advanced Financial Network.
HOME» NASDAQ » G » GILD Stock Price » GILD Stock News

Gilead Sciences Share News

 Gilead Sciences (mm) Stock Price
GILD Stock Price
 Gilead Sciences (mm) Stock Chart
GILD Stock Chart
 Gilead Sciences (mm) Stock News
GILD Stock News
 Gilead Sciences (mm) Company Information
GILD Company Information
 Gilead Sciences (mm) Stock Trades
GILD Stock Trades

Idenix: 89% of Patients in Hep C Trial Arm Achieved Viral Suppression

By Ben Fox Rubin Biopharmaceutical firm Idenix Pharmaceuticals Inc. (IDIX) has provided some results from an ongoing Phase 2b study of its lead hepatitis C drug, IDX184, showing positive suppression of the virus. Shares jumped 15% after hours Tuesday to $10.79, as the company's stock often moves sharply following reports related to its or its competitors' hepatitis C drugs. As of the market close, the shares were up 26% so far this year. Idenix is among a handful of companies scrabbling to develop a marketable all-oral Hepatitis C drug, with demand for the treatment expected to be worth billions of dollars a year. Gilead Sciences Inc. (GILD) is a main competitor of Idenix in the race develop such a drug; it spent $11 billion to buy Pharmasset this year, in part to obtain its lead hepatitis C drug candidate, GS-7977. In the Idenix study, Idenix used a mix of its IDX184 with older medications interferon and ribavirin. In all, 31 patients were enrolled and 18 reached extended rapid virologic response, which is when the virus becomes undetectable at four weeks of treatment and again at 12 weeks of treatment. Of those 18 patients, nine were given additional treatments for 12 more weeks. All but one of them achieved sustained virologic response, or undetectable traces of the virus, a month after treatment ended. The other nine patients and those who didn't reach extended rapid virologic response are continuing a regimen of 36 weeks of treatment. Write to Ben Fox Rubin at

Stock News for Gilead Sciences (GILD)
10/25/201617:00:00Gilead Sciences to Release Third Quarter 2016 Financial Results...
10/25/201608:20:00Merck Profit Rises on Cancer Drugs, Vaccines
10/24/201617:00:00Gilead Sciences to Present at the Credit Suisse 25th Annual Healthcare...
10/24/201606:24:00Gilead Presents Results from Phase 3 Studies Evaluating Switching...
10/20/201610:07:00Gilead Announces SVR12 Rates From Four Phase 3 Studies of a Once-Daily...
10/20/201610:05:00Gilead Announces Top-Line Phase 2 Results for GS-4997 (Selonsertib...
10/06/201612:30:00Singapore's Temasek Hires Veteran Goldman Banker
10/05/201612:54:17Statement of Changes in Beneficial Ownership (4)
10/04/201618:03:00FDA Warns on Hepatitis C Drugs
10/03/201619:53:39Statement of Changes in Beneficial Ownership (4)
09/27/201616:05:00Gilead Sciences and the World Health Organization Announce Five-Year...
09/26/201616:56:18Statement of Changes in Beneficial Ownership (4)
09/21/201619:05:00Gilead Sciences Halts Test of Bowel Disease Treatment
09/21/201617:00:00Gilead Terminates Phase 2/3 Study of GS-5745 in Patients With...
09/20/201617:09:06Current Report Filing (8-k)
09/19/201616:47:49Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)
09/16/201606:06:02Free Writing Prospectus - Filing Under Securities Act Rules 163/433...
09/15/201622:01:00Gilead Prices $5 Billion of Senior Unsecured Notes
09/15/201608:58:00Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)
09/13/201610:25:57Confidential Treatment Order (ct Order)

Gilead Sciences and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations